ライフサイエンスコーパス: type 1

1 ofibromas in patients with neurofibromatosis type 1.

2 ated with human immunodeficiency virus (HIV) type 1.

3 and morphologically disparate range of cell types [1].

4 ed for neutralizing antibodies to poliovirus types 1, 2, and 3 in 580 younger and 297 older children.

5 ENP demonstrated age-associated increases in type 1/2/3 mediators as well as CT scores.

6 h factors (A), type-2/3 cytokines (B), mixed type-1/2/3 cytokines (C), and chemokines (D) that correl

7 izations with T-dependent and T-independent (Type 1) Ags, but Ab responses to a multivalent T-indepen

8 ibited multiple HIV genotypes, including HIV-type 1 and 2 and synergistically inhibited HIV in combin

9 a-cells is the central pathological event in type 1 and 2 diabetes, which has led to efforts to ident

10 Transplantation of stable TWIST1 rEC into a type 1 and 2 diabetic full-thickness splinted wound heal

11 highly correlated with ACE2 overlapped with type 1 and 2 IFN signatures, normally induced by viral i

12 Type 1 and advanced type 2 diabetes treatment involves d

13 pic and functional dichotomy between IRF8(+) type 1 and IRF4(+) type 2 conventional dendritic cells (

14 Children with neurofibromatosis type 1 and symptomatic inoperable plexiform neurofibroma

15 Neutrophils were highly responsive to type 1 and type 2 cytokine stimulation but did not respo

16 of beta-cell mass in the pathophysiology of type 1 and type 2 diabetes by enabling noninvasive quant

17 Both type 1 and type 2 diabetes increase the risk of atherosc

18 Type 1 and type 2 diabetes mellitus (T1DM and T2DM) incr

19 and improve quality of life for people with type 1 and type 2 diabetes with reduced beta-cell functi

20 been implicated in the pathogenesis of both type 1 and type 2 diabetes.

21 nglet oxygen and superoxide ion through both type 1 and type 2 pathways, alleviating the aerobic requ

22 Classical DCs include type 1 and type 2 subsets, which can detect different pa

23 lls subjected to model treatments that mimic type-1 and type-2 diabetic conditions and discovered str

24 PKA in spiny projection neurons that express type-1 and type-2 dopamine receptors are dichotomous, su

25 ACE2 together with angiotensin receptor types 1 and 2 and ACE2 are components of the renin-angio

26 In types 1 and 2 APDS, the PI3K-delta hyperactivity resulti

27 CAII(-) progenitor-like cells in the MPDs of types 1 and 2 diabetes donors, regardless of the duratio

28 sin II, which activates angiotensin receptor types 1 and 2, and angiotensin 1-7 and alamandine, which

29 Seroconversion rates for poliovirus types 1 and 3, respectively, were 98.9% (95%CI:96.7-99.8

30 uclear protein expression of IP(3)R1 (IP(3)R-type 1) and of phosphorylated CaMKII (immunohistochemist

31 ulation enhances the angiotensin II receptor type 1 (AT(1) R) axis associated with oxidative stress.

32 Vegfa is predominantly expressed by alveolar type 1 (AT1) cells and locally required to specify a sub

33 Type 1 (B1(V)) and type 2 (B2(V)) virions package genomi

34 ) 17 type-3 BrS pattern patients not showing type-1 BrS pattern after ajmaline (ajmaline-negative); (

35 le included (1) 15 patients with spontaneous type-1 Brugada pattern, and (2) 18 patients with ajmalin

36 Type 1 bubbles formed in eyes with significantly lower a

37 ological diseases such as myotonic dystrophy type 1, but its binding mechanism remains unclear.

38 peripherally restricted cannabinoid receptor type 1 (CB1R) inhibitors, which are devoid of the neurop

39 L did increase humoral responses, it blunted type 1 CD4(+) T cell responses against the SIV envelope

40 ing the CD103(+) conventional dendritic cell type 1 (cDC1) subpopulation important for antigen cross-

41 ss of Cyp26b1 leads to reduction of alveolar type 1 cells, failure of alveolar inflation and early po

42 d their terminal differentiation to alveolar type-1 cells.

43 Type 1 cGMP-dependent protein kinases (PKGs) play import

44 Sphingolipids included HBGA-related type 1 chain glycosphingolipids (GSLs), with HBGA epitop

45 Type 1 classical DCs (cDC1), which depend on the transcr

46 in the presence of treatment-naive quiescent type 1 CNV and by a factor of 0.46 (95% CI, 0.41-0.51) i

47 atible with a potential protective effect of type 1 CNV on the RPE and overlying neurosensory retina.

48 s co-localizing with quiescent and exudative type 1 CNV.

49 CI, 0.41-0.51) in the presence of exudative type 1 CNV.

50 ibution of vision loss and neurofibromatosis type 1 co-diagnosis within a large sample.

51 in (FN)-coated surface (-14.8%) but not on a type 1 collagen (COL1)-coated surface.

52 None of the Type 1 conjugates were catalytically active, whereas all

53 Type 1 conventional DCs are essential for PD-L1 blockade

54 Type 1 conventional dendritic cells (cDC1s) are typicall

55 d two Cu(II) coordination geometries: in the type 1 coordination observed in OvPrP at residues A136,

56 neurons (SPNs) expressing dopamine receptor type 1 (D1-SPNs) or 2 (D2-SPNs) in mice, we demonstrate

57 del, we show in this study that conventional type 1 dendritic cell IL-27 production in the draining l

58 dence indicates Batf3-dependent conventional type 1 dendritic cells (cDC1s) rarely found within the t

59 required for the development of conventional type 1 dendritic cells that are essential for cross-pres

60 g in mothers of children with presymptomatic type 1 diabetes (3 [1-7]) compared with mothers of child

61 nal hypoxia, in adolescents with and without type 1 diabetes (T1D) and relate the ratio to albuminuri

62 cts (POEs), have been hypothesised to affect type 1 diabetes (T1D) and rheumatoid arthritis (RA).

63 The pathogenesis of Type 1 diabetes (T1D) arises from the destruction of ins

64 High-affinity islet autoantibodies predict type 1 diabetes (T1D) but do not cause beta cell destruc

65 Therapeutic approaches to combat type 1 diabetes (T1D) include donor pancreas transplanta

66 Type 1 diabetes (T1D) is a significant problem in Indian

67 Type 1 diabetes (T1D) is a T cell-mediated autoimmune di

68 Type 1 diabetes (T1D) is an autoimmune disease of insuli

69 Although the etiology of type 1 diabetes (T1D) is not well understood, it is beli

70 The rising prevalence of type 1 diabetes (T1D) over the past decades has been lin

71 euronal components play an important role in type 1 diabetes (T1D) pathogenesis.

72 Optimal immune-based therapies for type 1 diabetes (T1D) should restore self-tolerance with

73 pool of beta cell-specific CD8(+) T cells in type 1 diabetes (T1D) sustains an autoreactive potential

74 pregenual anterior cingulate cortex (ACC) in type 1 diabetes (T1D) without depression affects emotion

75 lar helper T (T(FH)) cells are implicated in type 1 diabetes (T1D), and their development has been li

76 ethylation may be involved in development of type 1 diabetes (T1D), but previous epigenome-wide assoc

77 Type 1 diabetes (T1D)-an autoimmune disease that destroy

78 cell (CTL)-mediated beta-cell destruction in type 1 diabetes (T1D).

79 development of islet autoantibodies (IA) and type 1 diabetes (T1D).

80 utoantigens is a characteristic of childhood type 1 diabetes (T1D).

81 sed as an alternative treatment strategy for type 1 diabetes (T1D).

82 entially causal associations with autoimmune type 1 diabetes (T1D).

83 herapeutic interventions in the treatment of type 1 diabetes (T1D).

84 fate of beta-cells and hence progression of type 1 diabetes (T1D).

85 and nitration free adducts in patients with type 1 diabetes (T1DM) during onset of microalbuminuria

86 rinol on kidney outcomes among patients with type 1 diabetes and early-to-moderate diabetic kidney di

87 which was similar in donors with and without type 1 diabetes and harbored variable effector/memory fr

88 induced in the liver of streptozocin-induced type 1 diabetes and high fat diet-induced type 2 diabete

89 omplex is involved in the mechanisms linking type 1 diabetes and hypertension.

90 t transplantation is an emerging therapy for type 1 diabetes and hypoglycemic unawareness.

91 ing 153 individuals aged 14 to 24 years with type 1 diabetes and screening hemoglobin A1c (HbA1c) of

92 s not known.METHODSWe studied 63 adults with type 1 diabetes classified by peak mixed-meal tolerance

93 or their bioavailability, are reduced during type 1 diabetes development.

94 erquartile range {IQR}, 65-71] years; median type 1 diabetes duration, 36 [IQR, 25-48] years; 52% fem

95 Its involvement in murine and human type 1 diabetes has recently been recognized through the

96 f islet autoimmunity (IA) and progression to type 1 diabetes in a prospective high-risk cohort.

97 Public health screening for type 1 diabetes in its presymptomatic stages may reduce

98 Anomalies we found in type 1 diabetes included (i) an increase of 'intermediat

99 nd support recent findings that suggest that type 1 diabetes includes abnormalities in the exocrine p

100 Type 1 diabetes is an autoimmune disease characterized b

101 Type 1 diabetes is an autoimmune disease resulting in se

102 ery and insulin-producing cell therapies for type 1 diabetes management.

103 he correction of dysglycemia associated with type 1 diabetes mellitus (allogenic islet transplantatio

104 es how genetic variation in a mouse model of type 1 diabetes mellitus (T1DM) affects long-distance ge

105 to the two main forms of diabetes mellitus - type 1 diabetes mellitus (T1DM) and type 2 diabetes mell

106 Type 1 diabetes mellitus (T1DM) has traditionally been c

107 immunotherapy at best delays progression of type 1 diabetes mellitus and points to opportunities to

108 d to be associated with an increased risk of type 1 diabetes mellitus in childhood, but the reasons a

109 Type 1 diabetes mellitus is believed to result from dest

110 higher risk of complications than those with type 1 diabetes mellitus.

111 cells from healthy donors and patients with type 1 diabetes or Sezary syndrome.

112 Interestingly, type 1 diabetes pancreata displayed significant reductio

113 of amyloid in intraportal islet implants of type 1 diabetes patients has been proposed as cause in t

114 outside the HLA DR-DQ region in the Finnish Type 1 Diabetes Prediction and Prevention (DIPP) study i

115 Forty type 1 diabetes recipients of intraportal islet cell gra

116 While the vast majority of type 1 diabetes research efforts have focused on endocri

117 Type 1 diabetes results from the autoimmune-mediated des

118 e, 6 to 21 years) with newly diagnosed overt type 1 diabetes to receive subcutaneous golimumab or pla

119 ratio, children 6 to 13 years of age who had type 1 diabetes to receive treatment with the use of eit

120 appraisal of the T-cell epitopes targeted in type 1 diabetes was completed over a decade ago, providi

121 tudy participants with HLA susceptibility to type 1 diabetes were collected.

122 rom 26 control subjects and 62 patients with type 1 diabetes with (n = 17) and without (n = 45) DSPN

123 lines derived from matched individuals with type 1 diabetes with and without retinopathy.

124 n-inferiority trial in 108 participants with type 1 diabetes, aged 10-21 years and using insulin pump

125 ONThese results indicate that in adults with type 1 diabetes, beta cell responsiveness to hyperglycem

126 Autoimmune beta-cell destruction leads to type 1 diabetes, but the pathophysiological mechanisms r

127 Among adolescents and young adults with type 1 diabetes, continuous glucose monitoring compared

128 ll-characterized cohort of participants with type 1 diabetes, followed for >23 years.

129 GFBPs were unchanged in individuals with pre-type 1 diabetes, suggesting that total IGF levels may re

130 of treatment in individuals at high risk for type 1 diabetes.

131 guide other disease-modifying approaches for type 1 diabetes.

132 with progression from islet autoimmunity to type 1 diabetes.

133 y improve glycemic outcomes in children with type 1 diabetes.

134 ber predicts moderate DR in adolescents with type 1 diabetes.

135 n reducing hypoglycemia in older adults with type 1 diabetes.

136 bition for treating autoimmune diseases like type 1 diabetes.

137 the exocrine pancreas in the pathogenesis of type 1 diabetes.

138 spectrometry method in 648 individuals with type 1 diabetes.

139 beta-agonists might be at increased risk of type 1 diabetes.

140 patients with autoimmune diseases, including type 1 diabetes.

141 ong 203 adults at least 60 years of age with type 1 diabetes.

142 es concerning the pathways leading to IA and type 1 diabetes.

143 pared with AAb(-) relatives of subjects with type 1 diabetes.

144 known whether this receptor affects BP under type 1 diabetes.

145 l of metabolites and lipids related to DR in type 1 diabetes.

146 trol subjects and those at various stages of type 1 diabetes.

147 1c) (P < 0.05), whereas BRS was preserved in type 1 diabetes.

148 autoreactive cells in the NOD mouse model of type 1 diabetes.

149 l in countering autoimmune diseases, such as type 1 diabetes.

150 eterioration in individuals at high risk for type 1 diabetes.

151 people for years following the diagnosis of type 1 diabetes; however, the physiologic significance o

152 Previous studies indicate that type-1 diabetes is associated with increased cardiac exp

153 sodes associated with fatal complications in type-1 diabetes patients.

154 s performed on CGM data of 148 subjects with type-1-diabetes.

155 Using type 1 diabetic (T1DM) mouse models together with cultur

156 NA levels are constitutively up-regulated in type 1 diabetic Akita mice; CAR spontaneously accumulate

157 I interferon, is expressed in the islets of type 1 diabetic individuals, and its expression and sign

158 Here, Akita mice, type 1 diabetic model, were treated with the visual pigm

159 and compared with age- and duration-matched type 1 diabetic rats (T1D) (60 mg/kg streptozotocin).

160 d glucose levels between 91 and 443 mg/dL in type 1 diabetic rats.

161 involved in storage lipid biosynthesis, two type-1 diacylglycerol acyltransferases (DGAT1) from rice

162 Maf-deficient CCR6(-) ILC3s revealed a hyper type 1 differentiation status, characterized by overexpr

163 ysfunction in the kidneys of mouse models of type 1 DKD.

164 In myotonic dystrophy type 1 (DM1), somatic mosaicism of the (CTG)n repeat exp

165 Myotonic dystrophy type 1 (DM1), the most common adult muscular dystrophy,

166 Among them is myotonic dystrophy type 1 (DM1), the most common form of adult on-set muscu

167 n Type 3, Immunoglobulin, and Thrombospondin type 1 domains, which are collectively present in hundre

168 central alphaherpesvirus, equine herpesvirus type 1 (EHV1), actually exploits beta-defensins to invad

169 In EUS group, EI occurred in 63 patients (type 1 EI in 35 and type 2 EI in 28), and no type 3 EI w

170 as the best reference genes combination for type 1 endometrial cancer (grades 1, 2 and 3), whereas f

171 s categorized as Kansas City classification: type 1: erythema; type 2: ulcers (2a: superficial ulcers

172 itch type 2 fibres and increased slow-twitch type 1 fibres, together with a glycolytic-to-oxidative m

173 se causing autoimmune polyendocrine syndrome type-1, form foci with increased PML body association.

174 Glutaric aciduria type 1 (GA1) is an inborn error of lysine degradation ch

175 actions between a type 3 M2 gene segment and type 1 genes.

176 xpression and identified glucose transporter type 1 (GLUT1).

177 Type 1 helper T (Th1) cells and Type 17 helper T (Th17)

178 Vaccination induced type 1 helper T-cell (Th1)-biased CD4 T-cell responses a

179 The human immunodeficiency virus type 1 (HIV-1) accessory protein Vpr enhances viral repl

180 that encounter human immunodeficiency virus type 1 (HIV-1) after sexual contact.

181 In a second study of 49 people with HIV type 1 (HIV-1) and active TB commencing antiretroviral t

182 protection from human immunodeficiency virus type 1 (HIV-1) and simian immunodeficiency virus (SIV) a

183 GP pseudotyped human immunodeficiency virus type 1 (HIV-1) and vesicular stomatitis virus (VSV) to m

184 The human immunodeficiency virus type 1 (HIV-1) capsid (CA) protein forms a conical latti

185 transmission of human immunodeficiency virus type 1 (HIV-1) continues to cause new pediatric cases of

186 shock-and-kill" human immunodeficiency virus type 1 (HIV-1) cure strategy involves latency reversal f

187 troviruses like human immunodeficiency virus type 1 (HIV-1) encode the viral infectivity factor (Vif)

188 exposed to the human immunodeficiency virus type 1 (HIV-1) every year, but not all acquire the virus

189 Human immunodeficiency virus type 1 (HIV-1) exploits a number of specialized microtub

190 Human immunodeficiency virus type 1 (HIV-1) infection persists despite years of antir

191 newly diagnosed human immunodeficiency virus type 1 (HIV-1) infection, but prospective US data are li

192 out its role in human immunodeficiency virus type 1 (HIV-1) infection.

193 r patients with human immunodeficiency virus type 1 (HIV-1) infection.

194 glycoprotein of human immunodeficiency virus type 1 (HIV-1) is an important target for the developmen

195 count, baseline human immunodeficiency virus type 1 (HIV-1) RNA, and CYP2B6 metaboliser genotype.

196 nical model for human immunodeficiency virus type 1 (HIV-1) vaccines, therapeutics, and cure strategi

197 transmission of human immunodeficiency virus type 1 (HIV-1) via breastfeeding is responsible for near

198 ategies against human immunodeficiency virus type 1 (HIV-1), but their assembly remains poorly unders

199 Nef protein of human immunodeficiency virus type 1 (HIV-1).

200 e, we show that human immunodeficiency virus type-1 (HIV-1) with HBV-associated amino acid substituti

201 report that GA inhibits Herpes simplex virus type 1 (HSV-1) by inhibition of both fusion and viral pr

202 ly, cells infected with herpes simplex virus type-1 (HSV-1) incorporated EdC and EdU at similar level

203 Herpes simplex virus type-1 (HSV-1), one of the most widely spread human viru

204 Increasing evidence implicates HSV type 1 (HSV1) in the pathogenesis of late-onset Alzheime

205 The human T-cell leukaemia virus type 1 (HTLV-1) subtype c is endemic to central Australi

206 Human T-lymphotropic virus type 1 (HTLV-1)-associated myelopathy (HAM) is an inflam

207 Human T-lymphotropic virus type-1 (HTLV-1) persists within hosts via infectious spr

208 mediated viral pathogenesis independently of type 1 IFN and virus replication.IMPORTANCE The inflamma

209 IL-4Ralpha), common to both IL-4R complexes: type 1 (IL-4Ralpha/gammac; IL-4 specific) and type 2 (IL

210 aling diminished the type 2 and enhanced the type 1 immune response that directed macrophage polariza

211 henotype in the gills and the suppression of type 1 immune responses.

212 stasis via their capacity to suppress innate type 1 immunity.

213 rculating NK cells are known to convert to a type 1 innate lymphoid cell (ILC1)-like phenotype in res

214 del to permanently "time stamp" NK cells and type 1 innate lymphoid cells (ILC1s) to characterize the

215 release Ca(2+) from intracellular stores via type 1 Ins(1,4,5)P(3)Rs were investigated.

216 nse to cell-intrinsic Toll-like receptor and type 1 interferon receptor signaling, upregulated an IRF

217 Women have a more robust type 1 interferon response during HIV infection relative

218 dendritic cells type 2 (cDC2) due to reduced type 1 interferon signalling.

219 Crigler Najjar type 1 is a rare autosomal recessive condition caused by

220 patients with leukocyte adhesion deficiency type 1 (LAD-1) had reduced C3 transcripts and diminished

221 We reported previously that type 1-like diabetes in rats accelerates the degradation

222 te synthase- and glucose transporter protein type 1-mediated arginolysis and glycolysis.

223 BTNL2 is a type-1 membrane protein that provides inhibitory signal

224 y (45.6%), followed by type 2 MI (34.2%) and type 1 MI (12%) (p < 0.001).

225 In ISCHEMIA, type 1 MI events using the primary and secondary definit

226 ts (median age 44 years; 30% women); 55% had type 1 MI, 32% had type 2 MI, and 13% had myocardial inj

227 long-term mortality among young adults with type 1 MI, type 2 MI, or myocardial injury.

228 terval: 1.4 to 5.1; p = 0.003) compared with type 1 MI.

229 In 38.8% of eyes, SLG were found overlying type 1 MNV, and in 44.9% of eyes, often those with more

230 he primary outcome was highest in those with type 1 myocardial infarction (cause-specific hazard rati

231 Events were retrospectively classified into type 1 myocardial infarction (T1MI, atherothombotic even

232 Implementation increased the diagnosis of type 1 myocardial infarction by 11% (510/4471), type 2 m

233 tion because of extensive disfigurement from type 1 neurofibromatosis and 6 weeks after complete loss

234 Neurofibromatosis type 1 (NF1) is a common cancer predisposition syndrome

235 Neurofibromatosis type 1 (NF1) is a common monogenic neurodevelopmental di

236 nsion (PH) associated with neurofibromatosis type 1 (NF1) is a rare and largely unknown complication

237 biallelic mutations in the neurofibromatosis type 1 (NF1) tumor suppressor gene.

238 gene (NF1) mutation causes neurofibromatosis type 1 (NF1), a disorder in which brain white matter def

239 This study reports on neurofibromatosis type 1 (NF1)-associated optic pathway gliomas (OPGs) and

240 d by withdrawal of Cup/Rap, proliferation of type 1 NSCs and dendritic spine densities of adult-born

241 ts with its receptor (interleukin 1 receptor type 1) on hematopoietic stem and progenitor cells in th

242 tations in breast cancer susceptibility gene type 1 or 2 (BRCA1/2) poses tissue-specific variations i

243 ter cross-sectional study, participants with type 1 or 2 diabetes volunteered between June 2015 and M

244 Patients with a diagnosis of type 1 or 2 diabetes with a clinical diagnosis of active

245 tory vomiting (idiopathic, associated with a type 1 or 2 diabetes, or postsurgical).

246 A is the main structural subunit of adhesive type 1 pili from uropathogenic Escherichia coli strains.

247 o the development of a chronic T helper cell type 1-polarized systemic immune response accelerated th

248 BGCs are non-ribosomal peptide synthetases, type 1 polyketide synthases, terpenes, and lantipeptides

249 increased the amount of glucose transporter type 1-positive cerebral blood vessels, reverted cerebra

250 ke compounds that open the two voltage-gated type 1 potassium (K(V)1) channels K(V)1.5 and Shaker, bu

251 While type 1 pRCC displays near absence of structural variants

252 While T-bet controls the type 1 programming of ILC3s, the molecular mechanisms go

253 In the myocardium, PKARIalpha (type-1 protein kinase A) can be reversibly oxidized, for

254 the ACE/angiotensin-II (Ang-II)/angiotensin type 1 receptor (AT1R) axis, a deleterious arm of RAS, u

255 hat act as antagonists of the angiotensin II type 1 receptor (AT1R).

256 To investigate the role of the cannabinoid type 1 receptor (CB1) in the formation of sensory maps i

257 -memory reconsolidation requires cannabinoid type 1 receptor (CB1R) signaling based on the fundamenta

258 Following activation of the melanocortin type 1 receptor (MC(1)), synovial fibroblasts acquire a

259 cental HIF-1alpha in an angiotensin receptor type 1 receptor agonistic autoantibody (AT(1) -AA)-induc

260 se single nucleotide polymorphism in the BMP type 1 receptor ALK6 (rs34970181;R371Q) associated with

261 ffect on GDF5 signaling, RGMs occupy the BMP type 1 receptor binding site similar to the observed int

262 nucleotide exchange factor 6, angiotensin-II type 1 receptor, endothelin type A receptor, lamin B1, B

263 Angiotensin II type-1 receptor (AT1R) antibodies have been associated w

264 ats via glucocorticoid-dependent cannabinoid type-1 receptor (CB1R)-mediated actions in the prelimbic

265 apical layer of the VNO such as vomeronasal type 1 receptors (V1R) in dominance behavior by using a

266 imple competition mechanism between RGMs and type 1 receptors as a possible basis for RGM-mediated GD

267 re mediated by different combinations of BMP type 1 receptors in a vessel bed-specific manner, offeri

268 s and transient receptor potential vanilloid type-1 receptors, indicating that this effect was caused

269 The TME already shows a reduction in type 1 regulatory T cells and PD-L1+ tumor-associated ma

270 n is a common modification of thrombospondin type 1 repeats present in metazoans and recently identif

271 high risk (with a Diabetes Prevention Trial-Type 1 Risk Score [DPTRS] >=6.75), the area under the cu

272 cephalic osteodysplastic primordial dwarfism type 1, Roifman syndrome, and Lowry-Wood syndrome.

273 structural outcomes than laser therapy when type 1 ROP is treated before 36 weeks' PMA.

274 py (cryo-EM) snapshots of ryanodine receptor type 1 (RyR1), a calcium-activated calcium channel engag

275 ant and WT duality is spinocerebellar ataxia type 1 (SCA1) caused by an ATXN1 polyglutamine protein,

276 the movement disorder spinocerebellar ataxia type 1 (SCA1) through a toxic gain-of-function mechanism

277 e ATXN1[82Q] model of spinocerebellar ataxia type 1 (SCA1), we explored the hypothesis that regional

278 t expansion disorder, spinocerebellar ataxia type 1 (SCA1).

279 Type 1 seroprevalence was 85% (95% CI 80%-89%) among you

280 Following Kodama classification one type 1, six type 2, two type 3, eight type 4, and two ty

281 ing plasma serine peptidase inhibitor Kunitz type-1 (SPINT1) concentrations at 36 weeks' gestation an

282 1-CD15-LDE225 via scavenger receptor class B type 1 (SR-B1) and CD15 on brain SHH MB cells in vitro,

283 tated in part by scavenger receptor class B, type 1 (SR-B1) that mediates HDL uptake into cells.

284 gy, treatment, and outcome of Crigler-Najjar type 1 syndrome (CN1) in 28 UGT1A1 c.222C>A homozygotes

285 This response was predominantly mediated by type-1 T helper cells, as demonstrated by the profiling

286 Overall, original features of types 1 (T1) and 2 (T2) in sCJDVV1 and -VV2, including r

287 nt C3 activity is integral to human T helper type 1 (Th1) and cytotoxic T cell responses.

288 ion and interferon-gamma-expressing T-helper type 1 (Th1) cells but increases in interleukin 5-expres

289 tors such as OAS1-3 and IFIT1-3 and T helper type 1 (Th1) chemokines CXCL9/10/11, as well as a reduct

290 ichment methods conclusively demonstrate EBV type 1 to be more prevalent in eBL patients than in geog

291 autoimmune disease-suppressing T regulatory type 1 (TR1) cells.

292 -evoked transient receptor potential ankyrin type 1 (TRPA1) activity and identify critical amino acid

293 of less proliferative diploid/2N lesions in Type 1 tumors.

294 Levels of 7 cytokines representative of type 1, type 2, and type 3 inflammation, and 21 lipid me

295 etes Study baseline cohort with recent-onset type 1/type 2 diabetes (n = 206/381) and age-matched glu

296 and subsets of consecutive participants with type 1/type 2 diabetes who reached the 5-year follow-up

297 e disruption results in the sensory disorder type 1 Usher syndrome (USH1).

298 The type of DM (type 1 vs. type 2) did not influence the rate of post-PP

299 tin, alpha smooth muscle actin, and collagen type 1 were equally distributed between the two IOLs and

300 tin, alpha smooth muscle actin, and collagen type 1 were performed.